Prediction of Response to Pegylated Interferon plus Ribavirin byIL28BGene Variation in Patients Coinfected with HIV and Hepatitis C Virus
| Autor: | Karin Neukam, Antonio Caruz, Antonio Rivero, Juan Macías, Jose C. Palomares, Angela Camacho, Juan A. Pineda, Antonio Martínez, Irene Salas, Carmen Roldan, Julián de la Torre, José A. Mira |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Microbiology (medical) Genotype Hepatitis C virus Hepacivirus HIV Infections Interferon alpha-2 medicine.disease_cause Antiviral Agents Polymerase Chain Reaction Polymorphism Single Nucleotide Polyethylene Glycols chemistry.chemical_compound Flaviviridae Pegylated interferon Ribavirin Humans Medicine biology business.industry Interleukins Interferon-alpha virus diseases Hepatitis C Hepatitis C Chronic Viral Load biology.organism_classification medicine.disease Virology Recombinant Proteins digestive system diseases Treatment Outcome Infectious Diseases chemistry Female Interferons business Viral load medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 51:788-795 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1086/656235 |
| Popis: | Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus (HCV)-monoinfected patients with genotype 1. Data on other genotypes and on patients coinfected with human immunodeficiency virus (HIV) and HCV are more limited. We aimed to assess the predictive ability of variations in the single-nucleotide polymorphism rs12979860 for SVR in HIV/HCV-coinfected patients, regardless of HCV genotype.The rs12979860 genotype was determined by polymerase chain reaction in 154 patients who had received therapy against HCV with pegylated interferon plus ribavirin.rs12979860 genotype was TT in 20 patients (13%), TC in 66 patients (43%), and CC in 68 patients (44%). Rates of SVR in patients with genotype CC and in those with genotype TC or TT, according to HCV genotype, were, respectively, 50% and 17% (P.001) in patients with genotype 1, 80% and 25% (P = .027) in patients with genotype 4, and 93% and 77% (P = .115) in patients with genotype 3. The median (interquartile range) low-density lipoprotein cholesterol level in patients with rs12979860 CC was 89 mg/dL (73-120 mg/dL) versus 75 mg/dL (55-91 mg/dL) (P = .001) in those with TC or TT. Independent predictors of SVR were HCV genotype 2-3 (odds ratio [OR], 13.98; 95% confidence interval [CI], 4.87-40.1; P.001), rs12979860 CC (OR, 5.05; 95% CI, 2.04-12.5; P.001), baseline plasma HCV RNA load ofor =600,000 IU/mL (OR, 1.99; 95% CI, 1.18- 3.34; P = .009), and female sex (OR, 4.28; 95% CI, 1.08-16.96; P = .039).IL28B gene variations independently predict SVR in HIV/HCV-coinfected patients with HCV genotype 1 and non-genotype 1 HCV infection. The association between rs12979860 and plasma low-density lipoprotein cholesterol suggests that the system low-density lipoprotein ligand/receptor might be involved in the effect of this genotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|